In Vitro: PF-07238025 (0.2-6 μM; 48 h) reduces pBCKDH in a dose-dependent manner in Hek293 cells, and increases BDK accumulation by 50%.
In Vivo: PF-07238025 (20 mg/kg, 100 mg/kg; 8 weeks) reduces glucose excursion after 2?days in HFD-fed mice, and leads significant reduction in both BCAAs and BCKAs by day 7.